FDA Approves Ensitrelvir to Prevent COVID-19 After Exposure - Takeaways - MDSpire

FDA Approves Ensitrelvir to Prevent COVID-19 After Exposure

Share

1

The FDA has approved ensitrelvir (XOCOVA) for postexposure prophylaxis of COVID-19 in individuals aged 12 and older.
2

Ensitrelvir is the first oral option approved to prevent COVID-19 following exposure to an infected individual.
3

The approval was based on the phase 3 SCORPIO-PEP trial, which enrolled 2,387 participants exposed to symptomatic COVID-19.
4

Ensitrelvir reduced the risk of symptomatic COVID-19 by 67% compared to placebo among uninfected participants.
5

The most common adverse events with ensitrelvir were headache, diarrhea, and cough, with overall rates similar to placebo.